Menu
Search
|

Menu

Close
X

TG Therapeutics Inc TGTX.OQ (NASDAQ Stock Exchange Capital Market)

5.11 USD
-- (--)
As of Oct 22
chart
Previous Close 5.11
Open --
Volume --
3m Avg Volume 351,129
Today’s High --
Today’s Low --
52 Week High 17.30
52 Week Low 4.91
Shares Outstanding (mil) 82.82
Market Capitalization (mil) 436.45
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.182
FY17
-1.917
FY16
-1.594
FY15
-1.383
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
2,867.64
6.55
Price to Book (MRQ)
vs sector
4.29
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
0.21
14.15
LT Debt to Equity (MRQ)
vs sector
0.00
11.31
Return on Investment (TTM)
vs sector
-160.75
12.83
Return on Equity (TTM)
vs sector
-165.11
14.95

EXECUTIVE LEADERSHIP

Michael Weiss
Executive Chairman of the Board, President, Chief Executive Officer, Since 2011
Salary: $525,000.00
Bonus: --
Sean Power
Chief Financial Officer, Treasurer, Corporate Secretary, Since 2011
Salary: $315,000.00
Bonus: --
Adam Waldman
Chief Commercial Officer, Since 2018
Salary: --
Bonus: --
Laurence Charney
Independent Director, Since 2012
Salary: --
Bonus: --
Yann Echelard
Independent Director, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2 Gansevoort St Fl 9
NEW YORK   NY   10014-1667

Phone: +1212.5544484

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.

SPONSORED STORIES